Latest News about ESALY
Recent news which mentions ESALY
Why Anavex Life Sciences Stock Bolted Higher in January
Today 10:16 EST
From Motley Fool
From Benzinga
From Motley Fool
From Motley Fool
This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich
January 17, 2023
From Motley Fool
From Motley Fool
Barron's Top Weekend Stock Picks: Tesla, Snowflake, Delta And Why Warren Buffett's Berkshire Hathaway May Be In For Big Tax Bill
January 07, 2023
From Benzinga
FDA approves treatment for people with mild forms of Alzheimer’s
January 06, 2023
From MarketWatch
From Benzinga
Lecanemab Alert: What Would Alzheimer’s Drug Approval Mean for Biogen (BIIB) Stock?
January 06, 2023
From InvestorPlace
1 Stock Defying the Downturn to Buy, and 1 to Avoid
January 06, 2023
From Motley Fool
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
From Benzinga
1 Green Flag and 1 Red Flag for Biogen
December 23, 2022
From Motley Fool
Biogen's Alzheimer's Antibody Might Have A Third Death Associated With
December 22, 2022
From Benzinga
Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug
December 20, 2022
From Benzinga
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
December 18, 2022
From InvestorPlace
Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock
December 18, 2022
From Motley Fool
Eating these simple foods may slow Alzheimer’s by a third
December 16, 2022
From MarketWatch
Why 2023 Could Be a Big Year for Biogen
December 07, 2022
From Motley Fool
Even After This Year’s Melt-Up, Runway Remains for LLY Stock
December 05, 2022
From InvestorPlace
Can These 2 Stocks Crush the Market Again in 2023?
December 04, 2022
From Motley Fool
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
November 30, 2022
From Benzinga
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
November 30, 2022
From Benzinga
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
November 28, 2022
From Benzinga
2 Stocks Near 52-Week Highs That Could Climb Higher
November 28, 2022
From Motley Fool
Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage
November 15, 2022
From Benzinga
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
November 14, 2022
From Benzinga
Why Shares Of Eli Lilly And Biogen Are Rallying Today
November 14, 2022
From Benzinga
Don't Get Used to Lower Medicare Part B Premiums -- Here's Why
October 29, 2022
From Motley Fool
Is Biogen a Buy After It Boosted Guidance?
October 26, 2022
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.